Company Recognition | Hillgene Recognized as a “Specialized and Innovative” Enterprise

Hillgene has recently been officially recognized as a “Specialized and Innovative” enterprise, a national designation granted by the Chinese government to companies that demonstrate outstanding capabilities in specialization, refinement, distinctive expertise, and continuous innovation.

This recognition is part of China’s industrial strategy to identify and support high-growth technology companies that play critical roles in advanced manufacturing and strategic emerging industries. Being selected as a “Specialized and Innovative” enterprise highlights Hillgene’s strong technological foundation and its growing influence within the biotechnology and cell therapy ecosystem.

The CGT industry is widely regarded as one of the most transformative areas in modern medicine. However, the path from early research to large-scale manufacturing often faces significant challenges, including fragmented processes across process development, vector production, and cell manufacturing.

To address these challenges, Hillgene has built an integrated “Plasmid–Virus–Cell” technology platform and developed All-in-One integrated solutions that cover the full process modules ranging from cell drug-specific plasmid construction and suspension serum-free viral production to fully closed and automated cell process development, providing one-stop support for R&D, commercial manufacturing, quality control, and regulatory submission in cell and gene therapy, and driving innovation across the life sciences industry.

Among them, Hillgene's unique HiLenti ™ Suspension serum-free lentivirus production platform utilizes 293T cell lines licensed from Stanford University and Merck, enabling high-quality and scalable lentiviral vector production and addressing the growing industry demand for reliable viral vectors.

In addition, Hillgene has established a 7,000 m² GMP manufacturing facility designed in compliance with NMPA, FDA, and EMA standards, supporting the entire manufacturing workflow from clinical trials to commercial production.

To date, Hillgene has:

1. Supported 15 IND submissions for CAR-T, TCR-T, and CAR-NK programs

2. Delivered 100+ lentiviral vector production projects

3. Achieved nearly 80% market share in the CAR-NK sector in China

4. Successfully passed 30+ domestic and 4 international client audits (all passed on the first attempt)

Beyond manufacturing, Hillgene is also building a CDMO + supply chain ecosystem, providing key materials, quality control solutions, and global technology transfer support to accelerate the development of innovative therapies.

Headquartered in Suzhou, China, Hillgene is committed to empowering global innovation in cell therapy and bridging the gap between scientific discovery and patient access.